Now part of Biogen
Reata Pharmaceuticals (reatapharma.com) scores 77 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 56th percentile of 17284 Healthcare brands.
Reata Pharmaceuticals was a clinical-stage biopharmaceutical company founded in 2002 and headquartered in Irving, Texas. It focused on developing experimental oral antioxidative and anti-inflammatory drugs to treat rare and severe diseases. The company has since been acquired by Biogen, and its therapeutic programs and legacy now continue as part of Biogen's broader portfolio of treatments for serious diseases.
| Brand Name | Reata Pharmaceuticals |
|---|---|
| Domain | reatapharma.com |
| Industry | Healthcare |
| Founded | 2002 |
| Headquarters | Irving |
| Parent Company / Owner | Wellington Management Company |
| Main Competitors | Vertex Pharmaceuticals (88/100), Alnylam Pharmaceuticals (87/100), BioMarin Pharmaceutical (84/100), Ultragenyx Pharmaceutical (79/100), Sarepta Therapeutics (83/100), Horizon Therapeutics (80/100) |
Moz Domain Authority 45/100 vs category average 40 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Reata Pharmaceuticals has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "Reata Pharmaceuticals has been acquired by Biogen." (Meta description: 7 words. OG description present but brief) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description, og:type, Twitter cards. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on X (Twitter), LinkedIn, Instagram; no detected presence on Facebook, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Reata Pharmaceuticals?", Claude could identify the brand as of October 2026. Reata Pharmaceuticals was a biopharmaceutical company focused on developing drugs for rare and life-threatening diseases, particularly those involving oxidative stress and inflammation. It developed omaveloxolone (Skyclarys), the first FDA-approved treatment for Friedreich's atax Best known for Developing Skyclarys (omaveloxolone), the first FDA-approved treatment for Friedreich's ataxia.
When asked "Best brands similar to Reata Pharmaceuticals?", Claude would recommend Reata Pharmaceuticals as of October 2026. It's notable in rare disease drug development and its flagship product Skyclarys was a landmark approval, making it relevant to mention despite now being part of Biogen.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Reata Pharmaceuticals's main competitors in Healthcare: Vertex Pharmaceuticals (88/100), Alnylam Pharmaceuticals (87/100), BioMarin Pharmaceutical (84/100), Ultragenyx Pharmaceutical (79/100), Sarepta Therapeutics (83/100).
Sources: Brand Analyzer scan
Reata Pharmaceuticals has moderate AI-search visibility, scoring 52/100 on Brand Analyzer's AI visibility composite (visibility 63, trust 39, recommendation 47). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Reata Pharmaceuticals official site
Reata Pharmaceuticals was founded in 2002. Reata Pharmaceuticals operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Reata Pharmaceuticals is headquartered in Irving. Reata Pharmaceuticals operates in the Healthcare category.
Sources: Wikidata
Reata Pharmaceuticals scores 47/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: Reata Pharmaceuticals official site
Reata Pharmaceuticals was a clinical-stage biopharmaceutical company that developed experimental oral antioxidative and anti-inflammatory drugs for rare and severe diseases. Founded in 2002 and based in Irving, Texas, the company has since been acquired by Biogen, and its programs now continue under Biogen's portfolio.
Sources: Reata Pharmaceuticals official site
Reata Pharmaceuticals can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Reata Pharmaceuticals official site
Reata Pharmaceuticals is owned by or part of Wellington Management Company. Reata Pharmaceuticals operates in the Healthcare category.
Sources: Wikidata
Reata Pharmaceuticals investigated and developed experimental oral drugs with antioxidative and anti-inflammatory properties, aimed at treating rare and severe diseases. Following its acquisition by Biogen, these therapeutic efforts continue as part of Biogen's broader biopharmaceutical operations.
Sources: Reata Pharmaceuticals official site
Reata Pharmaceuticals scores 52/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Reata Pharmaceuticals has a limited AI-visibility profile at 52/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (63/100) and its weakest is trust (39/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a Moz Domain Authority of 45/100. The main gaps holding it back: thin schema.org structured data. In a live check, Claude could already identify Reata Pharmaceuticals from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Reata Pharmaceuticals: Reaction Biology (77/100), Reach Out and Read (77/100), RedCliff Ascent (77/100), Товариство Червоного Хреста України (Ukrainian Red Cross) (77/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.